Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi‐center, single‐arm, open‐label, phase 2 study
American Journal of Hematology · 2023-04 · 98 (4) · 571-579
DOI: 10.1002/ajh.26826 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift American Journal of Hematology, online erschienen am 22.01.2023. Verfasst von Wei Xu und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Pukou CLL Center, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Inn…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Orelabrutinib is a novel, small molecule, selective irreversible Bruton's tyrosine kinase inhibitor. The aim of this study was to evaluate the efficacy and safety in patients with refractory or relapsed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). This is single‐arm, multi‐center, open‐label, phase 2 study in 80 eligible Chinese patients, who were treated with monotherapy of orelabrutinib at 150 mg once daily. Overall response rate evaluated by an independent review committee was the primary endpoint, and secondary endpoints include progression‐free survival, overall survival, and safety. Independent review committee assessed overall response rate was 92.5% (74/80); complete response 21.3% (17/80), partial response 60.0% (48/80), partial response with lymphocytosis 11.3% (9/80). At a 32.3‐month median follow‐up, the median progression‐free survival had not been achieved, while the 30‐month progression‐free survival rate and overall survival rates were 70.9% (95% confidence interval [CI], 59.5–79.6) and 81.3% (95% CI, 70.8–88.2), respectively. Orelabrutinib also revealed substantial response in patients with high prognostic risks: overall response rates of patients carrying positive TP53 mutational status or del(17p), del(11q), as well as unmutated immunoglobulin heavy‐chain variable region gene were 100%, 94.7%, and 93.9%, respectively. Most adverse events were in low grade, with 86.8% of AEs being Grade 1 or 2. Nearly 67% of patients were still receiving orelabrutinib after almost a 3‐year follow‐up. In conclusion, Orelabrutinib demonstrated compelling efficacy as well as safety profiles, with a noteworthy number of patients obtaining complete response in refractory or relapsed CLL/SLL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Pukou CLL Center, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, People's Rep…
- Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, People's Republic of China.
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
- Department of Hematology, Peking University People's Hospital, Beijing, People's Republic of China.
- Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.
- Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
ORCID-Profile: Keshu Zhou, Yu Hu, Jianfeng Zhou, Bing Xu, Ting Liu, Jianda Hu, Chunyan Ji, Shuo Ma
Zitieren
APA
Xu, W., Zhou, K., Wang, T., Yang, S., Liu, L., Hu, Y., Zhang, W., Ding, K., Zhou, J., Gao, S., Xu, B., Zhu, Z., Liu, T., Zhang, H., Hu, J., Ji, C., Wang, S., Xia, Z., Wang, X., …, & Li, J. (2023). Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi‐center, single‐arm, open‐label, phase 2 study. American Journal of Hematology, 98(4), 571-579. https://doi.org/10.1002/ajh.26826
Vancouver
Xu W, Zhou K, Wang T, Yang S, Liu L, Hu Y, et al. Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi‐center, single‐arm, open‐label, phase 2 study. American Journal of Hematology. 2023;98(4):571-579. doi:10.1002/ajh.26826
BibTeX
@article{Xu2023,
author = {Xu, Wei and Zhou, Keshu and Wang, Tingyu and Yang, Shenmiao and Liu, Lihong and Hu, Yu and Zhang, Wei and Ding, Kaiyang and Zhou, Jianfeng and Gao, Sujun and Xu, Bing and Zhu, Zunmin and Liu, Ting and Zhang, Huilai and Hu, Jianda and Ji, Chunyan and Wang, Shunqing and Xia, Zhongjun and Wang, Xin and Li, Yan and Song, Yongping and Ma, Shuo and Tang, Xinran and Zhang, Bin and Li, Jianyong},
title = {Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi‐center, single‐arm, open‐label, phase 2 study},
journal = {American Journal of Hematology},
year = {2023},
volume = {98},
number = {4},
pages = {571--579},
doi = {10.1002/ajh.26826}
}
EUVIMED